SequelSEC

ZyVersa Therapeutics, Inc. ZVSA

Pharmaceutical Preparations · CIK 0001859007 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$25.49M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

ZyVersa Therapeutics, Inc. (ZVSA) reported net income of -$24.95M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from ZyVersa Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ZyVersa Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$25.49M-$9.14M-$107.75M
Net income-$24.95M-$9.41M-$98.30M
Research & development$1.11M$1.78M$3.21M
Weighted-average diluted sharesshares 5.96Mshares 1.11MUnavailable
Pretax income-$25.80M-$9.41M-$107.75M
Income tax expense-$851.66K$6.74K-$9.46M
Diluted EPS$-4.18$-8.48$-1,089.70
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$5.73M$7.36M$11.21M
Selling & marketingUnavailableUnavailableUnavailable

Balance

ZyVersa Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalentsUnavailableUnavailableUnavailable
Total assets$463.45K$20.60M$22.11M
Current assets$463.45K$1.72M$3.35M
Total liabilities$12.85M$12.08M$11.04M
Current liabilities$12.85M$11.23M$10.19M
Total equity incl. NCI-$12.39M$8.52M$11.07M
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$10.12M$9.34M$8.43M

Cash flow

ZyVersa Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$5.11M-$7.52M-$8.72M
Capital expendituresUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailable
Financing cash flow$3.69M$5.91M$5.96M
Net change in cash-$1.43M-$1.61M-$2.76M
Stock-based compensation$222.83K$705.57K$1.19M
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

ZyVersa Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flowUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio0.04x0.15x0.33x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ZVSA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-19View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-12View SEC filing
10-K · Filed 2025-03-27View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.